Home » NEWS » Health » Hawthorn executes deal with university

Hawthorn executes deal with university

MADISON — Hawthorn Pharmaceuticals Inc. has struck a global licensing deal with the University of Pittsburgh covering a series of novel monoclonal antibodies for cancer.

Under the terms of the agreement, Madison-based Hawthorn will receive an exclusive worldwide license to develop and commercialize the antibody portfolio.

“We are excited to be working with the world=-class cancer scientists at University of Pittsburgh’s Cancer Institute who have devoted their entire careers to improving people’s lives through cancer discovery,” said Rob Lewis, chief scientific officer at Hawthorn.

“There are many strengths created by our relationship with the University of Pittsburgh that promotes the rapid development of these novel antibodies,” said Max Draughn, president and CEO of Hawthorn. “Our collaboration is a shared vision to ultimately extend and improve the lives of many children and adults who suffer with various cancers.”


… we’d like to ask for your support. More people are reading the Mississippi Business Journal than ever before, but advertising revenues for all conventional media are falling fast. Unlike many, we do not use a pay wall, because we want to continue providing Mississippi’s most comprehensive business news each and every day. But that takes time, money and hard work. We do it because it is important to us … and equally important to you, if you value the flow of trustworthy news and information which have always kept America strong and free for more than 200 years.

If those who read our content will help fund it, we can continue to bring you the very best in news and information. Please consider joining us as a valued member, or if you prefer, make a one-time contribution.

Click for more info

About Wally Northway

Leave a Reply